Genmab — Maj 2019
-
Tak for forklaringer til, Solsen, Sukkeralf og EL...
-
Har man for mange Genmab aktier når ens humør påvirkes af aktiekursen ?
-
Jeg har ofte de samme tanker Tandfeen.
-
Genmab udgør også 99,4 % af mine aktier
-
Andrew Carlsen First of all no setbacks in AXL...
Andrew Carlsen Enapotamab (Humax-Axl) continues to be a program that we are very excited about. It
should be noted that Enapotamab is the asset that is progressed the furthest after
Tisotumab and we expect data at ASCO from the Ph I dose escalation study in
NSCLC and in H219 we should get meaningful data from the expansion cohort. -
Det er en kende mere end halvdelen, men jeg har faktisk ofte tænkt over, om jeg skulle reducerer i dem - på ingen måde fordi, at jeg ikke tror på fremtiden, men fordi det påvirker mit humør både op og ned.
-
-
Tilgengæld er der ikke så meget at holde øje med
-
Det er korrekt og klart en fordel
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind